Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir and PegIFN-2b in Chronic Hepatitis B
NCT01727271Phase 4Withdrawn
- Sponsor
- Merck & Co.
- Start
- Aug 2013
- Primary completion
- Aug 2017
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
A Phase 4 trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB), sponsored by Merck & Co.. Planned start Aug 2013; status: withdrawn.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01727271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01727271.